Aurinia Pharmaceuticals Inc (TSE:AUP) (NASDAQ:AUPH) – Stock analysts at Seaport Global Securities dropped their Q4 2017 EPS estimates for Aurinia Pharmaceuticals in a research report issued on Wednesday. Seaport Global Securities analyst V. Bernardino now forecasts that the company will post earnings per share of ($0.10) for the quarter, down from their previous estimate of ($0.05). Seaport Global Securities currently has a “Buy” rating on the stock. Seaport Global Securities also issued estimates for Aurinia Pharmaceuticals’ FY2019 earnings at ($0.24) EPS and FY2020 earnings at ($0.11) EPS.

WARNING: “Q4 2017 EPS Estimates for Aurinia Pharmaceuticals Inc Reduced by Analyst (AUP)” was published by Watch List News and is the property of of Watch List News. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at

Aurinia Pharmaceuticals (AUP) opened at C$6.56 on Friday. Aurinia Pharmaceuticals has a 52 week low of C$2.75 and a 52 week high of C$14.17.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.